Adverse Changes in HbA1c, Body Weight and Insulin Use in People with Type 1 Diabetes Mellitus Following Dapagliflozin Discontinuation in the DEPICT Clinical Trial Programme

Lignende værker

• SAT-LB025 Analysis of Benefit/Risk in the Subgroup of Patients with BMI of >=27 Kg/m(2) in the Dapagliflozin DEPICT-1 and -2 Trials in Type 1 Diabetes
  af: Mathieu, Chantal, et al.
  Udgivet: (2019)
• Benefit/risk profile of dapagliflozin 5 mg in the DEPICT‐1 and ‐2 trials in individuals with type 1 diabetes and body mass index ≥27 kg/m(2)
  af: Mathieu, Chantal, et al.
  Udgivet: (2020)
• Long‐term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT‐2 study): 52‐week results from a randomized controlled trial
  af: Mathieu, Chantal, et al.
  Udgivet: (2020)
• Changes in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy: a primary care database study
  af: Scheerer, Markus F, et al.
  Udgivet: (2016)
• Long‐term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52‐week outcomes from the DEPICT‐1 and ‐2 studies
  af: Phillip, Moshe, et al.
  Udgivet: (2020)